



Access to medicines in England

Based on medicine and vaccine indications approved by the European Medicines Agency (EMA) between 2022 – 2025, only half (53%) are currently available to patients on the NHS.





Excluding indications which obtained access via a non-NICE route, **under half of the EMA-approved indications (159/366) have received a positive NICE recommendation**




Of the EMA-approved indications, **a quarter (113/439) are still waiting for an appraisal or decision from NICE**

N.B. 50 of the 113 indications awaiting a NICE decision were approved by the EMA in 2025. Given the NICE appraisal process takes approx. one year, these indications may soon have a recommendation.



Of the positive NICE recommendations **42% (66/159), do not provide access to the full patient population** (i.e. an "optimised" appraisal)



Of the EMA-approved indications which reached NICE, **over a quarter (61/220) were either terminated or received a negative recommendation**

Understanding the graphic

- **EMA total** = All indications approved by the EMA from January 2022 to the end of December 2025, excluding minor extensions such as small changes to age ranges or patient weight limits.
- **Non-NICE access** = Indications available in England through routes other than a NICE appraisal, such as NHS specialised commissioning, vaccines, or medicines with UK sales data showing they are being used.
- **Reached NICE** = Indications that have been considered by NICE.
- **No UK data** = Includes medicines which have been approved by the MHRA, but have not been assessed by NICE, do not appear in NICE's forward work programme and show no evidence of any UK sales. On that basis, these medicines are assumed not to be available to NHS patients, with no future plans to make these medicines available.
- **No MHRA approval** = Indications which have a licence from the EMA for use in Europe, however, do not have a licence from the MHRA for use in the UK
- **NICE pipeline** = Indications that are awaiting assessment or are in development by NICE as of the end of 2025.
- **Completed NICE appraisal** = Indications where NICE reached a final decision to recommend or not recommend use on the NHS. This does not include terminated appraisals.
- **Recommended for use on the NHS** = Indications that NICE recommended for use on the NHS, either in full or for a narrower group of patients.
- **Full recommendation** = Indications recommended by NICE for use in line with the full marketing authorisation.

- **Optimised** = Indications recommended by NICE for only part of the licensed patient population.
- **Not recommended** = Indications that NICE decided not to recommend for use on the NHS.
- **Terminated** = Indications where the NICE appraisal was stopped before a final recommendation was made or no submission was made by the company.
- **Footnotes:**
 - Indications are the different diseases or groups of patients within a disease which a medicine or vaccine can be used for. Different indications for a medicine or vaccine tend to be approved at different times, hence the graphic above considers the data on an indication, rather than medicine / vaccine level, to provide as detailed a picture as possible.
 - *The graphic assesses approvals by NICE and therefore focuses on access to medicines in England. For a medicine to be available in Scotland, it must be approved by the Scottish Medicines Consortium (SMC). For a medicine to be available in Wales and Northern Ireland, often a NICE recommendation suffices, however the All-Wales Medicines Strategy Group (AWMSG) also carry out their own appraisals on certain medicines that NICE has not evaluated.